'''Nilestriol''' ([[International Nonproprietary Name|INN]]) (brand name '''Wei Ni An'''; developmental code name '''LY-49825'''), also known as '''nylestriol''' ([[United States Adopted Name|USAN]], [[British Approved Name|BAN]]), is a [[Organic compound#Synthetic compounds|synthetic]], [[steroid]]al [[estrogen]] that was patented in 1971<ref>{{cite book|title=Official Gazette of the United States Patent and Trademark Office: Patents|url=https://books.google.com/books?id=vLk5AQAAMAAJ|year=1975|publisher=U.S. Department of Commerce, Patent and Trademark Office|page=1677}}</ref> and is marketed in [[China]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA891|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=891–}}</ref><ref name="Drugs.com">https://www.drugs.com/international/nilestriol.html</ref> It is the [[cyclopentane|3-cyclopentyl]] [[ether]] of [[ethinylestriol]], and is also known as '''ethinylestriol cyclopentyl ether''' ('''EE3CPE''').<ref name="McGuire2013">{{cite book|author=William McGuire|title=Experimental Biology|url=https://books.google.com/books?id=q9HkBwAAQBAJ&pg=PA161|date=14 December 2013|publisher=Springer Science & Business Media|isbn=978-1-4757-4673-0|pages=161–}}</ref> Nilestriol is a [[prodrug]] of ethinylestriol, and is a more [[potency (pharmacology)|potent]] estrogen in comparison.<ref name="McGuire2013" /> It is described as a slowly-[[metabolism|metabolized]], long-acting estrogen and derivative of [[estriol]].<ref name="Schoenberg1977">{{cite book|author=Daniel Robert Schoenberg|title=Biochemical Properties of the Cytoplasmic Estrogen Receptors from Immature Rat and Mature Rabbit Uteri|url=https://books.google.com/books?id=oXrTAAAAMAAJ|year=1977|publisher=University of Wisconsin|page=A-17}}</ref><ref name="ExcerptaMedica1978">{{cite book|title=Excerpta medica. Section 10: Obstetrics and gynecology|url=https://books.google.com/books?id=55-aAAAAIAAJ|year=1978}}</ref> Nilestriol was assessed in combination with [[levonorgestrel]] for the potential treatment of [[menopause|postmenopausal]] [[osteoporosis]], but this formulation ultimately was not marketed.<ref name="Aronson2009">{{cite book|author=Jeffrey K. Aronson|title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA173|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=173–}}</ref>
